The PYNNACLE study is a phase 1/2 clinical trial investigating a new medication called Rezatapopt. The study is aimed at patients with various advanced or metastatic cancers (e.g., ovarian, breast, lung, or endometrial cancer) whose tumor has a specific genetic alteration called the TP53-Y220C mutation. The objective is to determine how safe and effective Rezatapopt is and which dose is most suitable.

Participation:

Further information about the study and centers where participation is possible can be found on the study homepage: https://www.pynnaclestudy.com/